anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Here we assess whether the volume of cerebral ischemia induced during glioma surgery may negatively impact survival independently of neurological function. We also evaluate the sensitivity of intraoperative MRI (iMRI) in detecting cerebral ischemia during surgery.
METHODS: We retrospectively reviewed 361 cranial surgeries that used a 3 Tesla iMRI. 165 patients met all inclusion criteria and were included in the final analysis. Diffusion weighted imaging (DWI) obtained during iMRI was compared to postoperative DWI obtained within 7 days of the operation in cases where no further resection occurred after the iMRI.
RESULTS: 42 of 165 patients (25%) showed at least some evidence of restricted diffusion on postoperative (poMRI). 37 of these 42 (88%) cases lacked evidence of restricted diffusion on iMRI, meaning iMRI had a false-negative rate of 88% and a sensitivity of 12% in assessing the extent of ischemic brain after surgery. In high-grade gliomas, the volume of restricted diffusion on poMRI was predictive of overall survival, independent of new functional deficits acquired during surgery (p = 0.011).
CONCLUSION: This study presents the largest case series to date analyzing the sensitivity of iMRI in detecting surgical ischemia. In high-grade gliomas, increased volume of ischemia correlated with worsening median overall survival (OS) irrespective of postoperative neurologic deficits. Future work will focus on improving intraoperative detection of ischemia during the hyperacute phase when interventions such as blood pressure modulation or direct application of vasodilator agents may be effective.
Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or death. Severe hypoglycemia requiring the assistance of another person and/or parenteral glucose infusion or glucagon administration has been observed in clinical trials with insulin, including trials with NovoLog.

The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations [ ]. Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of hypoglycemia [ ]. As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., patients who are fasting or have erratic food intake). The patient’s ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. see Clinical Pharmacology (12)see Drug Interactions (7)

Rapid changes in serum glucose levels may induce symptoms of hypoglycemia in persons with diabetes, regardless of the glucose value. Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as longstanding diabetes, diabetic nerve disease, use of medications such as beta-blockers, or intensified diabetes control [ ]. These situations may result in severe hypoglycemia (and, possibly, loss of consciousness) prior to the patient’s awareness of hypoglycemia. Intravenously administered insulin has a more rapid onset of action than subcutaneously administered insulin, requiring more close monitoring for hypoglycemia. see Drug Interactions (7)
The side effects most frequently reported with phenothiazine compounds are extrapyramidal symptoms including pseudoparkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, and hyperreflexia. Muscle rigidity sometimes accompanied by hyperthermia has been reported following use of fluphenazine decanoate. Most often these extrapyramidal symptoms are reversible; however, they may be persistent (see below). The frequency of such reactions is related in part to chemical structure: one can expect a higher incidence with fluphenazine decanoate than with less potent piperazine derivatives or with straight-chain phenothiazines such as chlorpromazine. With any given phenothiazine derivative, the incidence and severity of such reactions depend more on individual patient sensitivity than on other factors, but dosage level and patient age are also determinants. 

Extrapyramidal reactions may be alarming, and the patient should be forewarned and reassured. These reactions can usually be controlled by administration of antiparkinsonian drugs such as Benztropine Mesylate or Intravenous Caffeine and Sodium Benzoate Injection, and by subsequent reduction in dosage.
Treating flexor tendon injuries within the digital flexor sheath (commonly referred to as palmar hand zone 2) presents both technical and logistical challenges. Success hinges on striking a delicate balance between safeguarding the surgical repair for tendon healing and initiating early rehabilitation to mitigate the formation of tendon adhesions. Adhesions between tendon slips and between tendons and the flexor sheath impede tendon movement, leading to postoperative stiffness and functional impairment. While current approaches to flexor tendon repair prioritize maximizing tendon strength for early mobilization and adhesion prevention, factors such as pain, swelling, and patient compliance may impede postoperative rehabilitation efforts. Moreover, premature mobilization could risk repair failure, necessitating additional surgical interventions. Pharmacological agents offer a potential avenue for minimizing inflammation and reducing adhesion formation while still promoting normal tendon healing. Although some systemic and local agents have shown promising results in animal studies, their clinical efficacy remains uncertain. Limitations in these studies include the relevance of chosen animal models to human populations and the adequacy of tools and measurement techniques in accurately assessing the impact of adhesions. This article provides an overview of the clinical challenges associated with flexor tendon injuries, discusses current on- and off-label agents aimed at minimizing adhesion formation, and examines investigational models designed to study adhesion reduction after intra-synovial flexor tendon repair. Understanding the clinical problem and experimental models may serve as a catalyst for future research aimed at addressing intra-synovial tendon adhesions following zone 2 flexor tendon repair.
OBJECTIVE: To construct nomogram models to predict the risk factors for early death in patients with metastatic melanoma (MM).
METHODS: The study covered 2138 cases from the Surveillance, Epidemiology, and End Results Program (SEER) database and all these patients were diagnosed with MM between 2010 and 2015. Logistic regression was performed to identify independent risk factors affecting early death in MM patients. These risk factors were then used to construct nomograms of all-cause early death and cancer-specific early death. The efficacy of the model was assessed with receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). In addition, external validation of the model was performed with clinicopathologic data of 105 patients diagnosed with MM at Sichuan Cancer Hospital between January 2015 and January 2020.
RESULTS: According to the results of logistic regression, marital status, the primary site, N staging, surgery, chemotherapy, bone metastases, liver metastases, lung metastases, and brain metastases could be defined as independent predictive factors for early death. Based on these factors, 2 nomograms were plotted to predict the risks of all-cause early death and cancer-specific early death, respectively. For the models for all-cause and cancer-specific early death, the areas under the curve (AUCs) for the training group were 0.751 (95% confidence interval [CI]: 0.726-0.776) and 0.740 (95% CI: 0.714-0.765), respectively. The AUCs for the internal validation group were 0.759 (95% CI: 0.722-0.797) and 0.757 (95% CI: 0.718-0.780), respectively, while the AUCs for the external validation group were 0.750 (95% CI: 0.649-0.850) and 0.741 (95% CI: 0.644-0.838), respectively. The calibration curves showed high agreement between the predicted and the observed probabilities. DCA analysis indicated high clinical application value of the models.
CONCLUSION: The nomogram models demonstrated good performance in predicting early death in MM patients and can be used to help clinical oncologists develop more individualized treatment strategies.
The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. The recording is passive without real-time EEG neurofeedback (i.e. constant brightness and volume).
People with DS may have some or all of these physical characteristics: a small chin, slanted eyes, poor muscle tone, a flat nasal bridge, a single crease of the palm, and a protruding tongue due to a small mouth and relatively large tongue. Other features include: a flat and wide face, a short neck, excessive joint flexibility, extra space between big toe and second toe, abnormal patterns on the fingertips and short fingers. Short stature is a characteristic feature of DS. Growth retardation of DS individuals starts prenatally. After birth, the growth velocity is most reduced between 6 months to 3 years . Growth charts specific for children with DS are important tools for routine medical follow-up, as well as early identification of pathological causes of growth retardation, and monitoring of growth promoting treatments. Growth charts for DS are available from different countries, for example, Italy, USA, Denmark, Sweden, Portugal, France, UK and Ireland and Saudi Arabia .
An injectable hydrogel network is provided distinguishing a non-covalently cross-linked hydrogel network with polymers functionalized with hydrophobic fatty pendant groups hydrophobically cross-linked with liposomal nanoparticles in which the liposomal nanoparticles are the cross-linkers. As the hydrogel is injectable, it is easily administered under the skin and does not require invasive surgical implantation. After injection the hydrogel rapidly self-heals to form a robust solid-like depot that can persist in the body over relevant timescales. The material does not cause a negative immune response like many other materials do. The hydrogel can gradually degrade over time in the body and therefore would not require surgical removal. Different embodiments modifying the surface chemistry of the liposomes give this hydrogel the ability to release therapeutic cargo, such as proteins, over controlled programmable timescales regardless of cargo size because the material can interact with the cargo through electrostatic or affinity interactions.
(-)-Epigallocatechin-3-O-gallate (EGCG), one of the green tea catechins, exhibits significant antioxidant properties that play an essential role in various diseases. However, the functional role and underlying mechanism of EGCG in stimulating of hepatic stellate cells (HSCs) remain unexplored in transcriptomics sequencing studies. The present study suggests that oral administration of EGCG at a dosage of 200 mg/kg/day for a duration of four weeks exhibits significant therapeutic potential in a murine model of liver fibrosis induced by CCl4. The activation of HSCs in vitro was dose-dependently inhibited by EGCG. The sequencing analysis data reveled that EGCG exerted a regulatory effect on the calcium signal in mouse HSCs, resulting in a decrease in calcium ion concentration. Further analysis revealed that EGCG inhibited the expression of phospholipase C epsilon-1 (PLCE1) and inositol 1, 4, 5-trisphosphate (IP3) in activated mouse HSCs. Additionally, EGCG contributes to the reduction the concentration of calcium ions by regulating PLCE1. After the knockdown of PLCE1, free calcium ion concentrations decreased, resulting in the inhibition of both cell proliferation and migration. Interestingly, the expression of PLCE1 and cytosolic calcium levels were regulated by reactive oxygen species(ROS). Furthermore, our findings suggest that ROS might inhibit the expression of PLCE1 by inhibiting TFEB, a transcription activator involved in the nuclear translocation process. Our study provided novel evidence regarding the regulatory effects of EGCG on activated HSCs (aHSCs) in mice by the calcium signaling pathway, emphasizing the crucial role of PLCE1 within the calcium signaling network of HSCs. The proposition was also made that PLCE1 holds promise as a novel therapeutic target for murine liver fibrosis.
A dispensing station comprises beneficial products for patients of a health care provider. An inventory database tracks inventory available in the dispensing station. A patient is associated with a prescription record, which specifies a prescribed beneficial product. The patient may provide patient identifying information to the dispensing station, such as credentialed payment information, which may be used to identify a prescription record, authenticate the patient, transfer a payment, and/or dispense the prescribed beneficial product to the patient. The prescription record may be valid for a limited time period, may be restricted to fulfillment within a particular location, and/or may be restricted to one or more specified dispensing stations. The dispensing station may validate the beneficial products before dispensing the products to the patient.
The invention provides a monoclonal antibody composition for quantitative detection of human body fluid amyloid and application thereof, belonging to the technical field of genetic engineering. The monoclonal antibody composition comprises a capture antibody AB7G and a detection antibody AB11A2, and is used for preparing a kit for quantitative detection of human body fluid amyloid, wherein the two antibodies are monoclonal antibodies secreted by cultured hybridoma cells AB7G and AB11A2 respectively. Both hybridoma cells were deposited with the China center for type culture collection. The kit specifically recognizes the Abeta 42 oligomer, the linear range of detection is 3.9-125 pg/mL, and the lowest detection limit is 7.8pg/mL. The core technology of the kit assembly mode is that monoclonal antibody AB7G is fixed on an ELISA plate to be used as a capture antibody, and the monoclonal antibody AB11A2 is marked and then diluted 1:2000 to be used as a detection antibody. And also relates to the heavy chain and light chain variable region genes of monoclonal antibodies AB7G and AB11A2 and the encoded polypeptides thereof. The invention also relates to the application of the antibody in preparing reagents and medicines for diagnosing Alzheimer disease.
The preparation method and application of dihydro-fraxinenone A relate to a new compound, a preparation method and application. The invention aims to provide a novel compound of dihydrochalcone A, a preparation method and application thereof. The molecular formula of the dihydro-fraxinenone A is C  14  H  16  O  4  The molecular weight is 248.1049. The preparation method comprises the following steps: 1. pulverizing cortex Dictamni Radicis, and extracting with ethanol; 2. dispersing the recovered ethanol extract with water, and sequentially extracting with petroleum ether, chloroform and ethyl acetate; 3. separating ethyl acetate extract by silica gel column chromatography, reversed phase silica gel column chromatography, hydroxypropyl dextran gel column chromatography, and preparative high performance liquid chromatography to obtain dihydrochalcone A. The dihydro-fraxinenone A is used for preparing anti-inflammatory drugs. IC of the present invention, dihydrofraxinone A, has NO release rate to LPS-induced inflammatory mouse macrophage (RAW 264.7)  50  It was 10.83. Mu.M/L, indicating a better anti-inflammatory activity in vitro. The invention belongs to the field of research on active ingredients of natural medicines.
NEW MATERIAL:The compound of formula I [R1 and R2 are (un)saturated long-chain fatty acid residue]. USE:An antitumor agent having sustained and promoted activity and low toxicity. PREPARATION:The objective substance can be produced e.g. by reacting a phosphatidylchloine-type glycerophospholipid of formula II (R3 is choline residue) with a nucleoside in the presence of phospholipase D and optionally a metallic ion in a solvent. The phospholipase D is preferably the one originated e.g. from Streptomyces sp-AA586 (FERM P-6100) and the reaction is preferably carried out at 25-45 deg.C for 30min to 2 days.
This is a Phase 2, prospective, multicenter, open-label, single-arm study of abiraterone acetate plus prednisone in men with non-metastatic, castration-resistant prostate cancer (CRPC) who have a rising PSA despite castrate levels of testosterone. The study consists of Screening Phase (up to 4 weeks), Core Study Treatment Phase (comprised of six 28-day cycles), a Pre-metastatic Disease Follow-up Phase, an Optional Drug Holiday Phase; and a 30-day Safety Follow-up Visit. Each treatment cycle will last 28 days. Participating participants will receive study agents (Abiraterone acetate 1000 mg/day plus prednisone 5 mg/day, orally) continually during the study. If the partcipants elects to participate in the Optional Drug Holiday Phase, participants will discontinue abiraterone acetate plus prednisone and ADT. Participants will have the option to return to study medication during the first year of the Optional Drug Holiday Phase if there is evidence of rising PSA but no metastasis based on study imaging. If participants do no elect to participate, they will continue with the core study treatment as per protocol. The study will end when all participated participants have disease progression or end of the 2-year period (if participants participated in the Optional Drug Holiday Phase). Participants will be required to return to the study site 30 days after receiving the last dose of abiraterone acetate for safety follow-up.
Oral transmucosal fentanyl citrate was investigated in clinical trials involving 257 opioid tolerant adult cancer patients experiencing breakthrough cancer pain. Breakthrough cancer pain was defined as a transient flare of moderate-to-severe pain occurring in cancer patients experiencing persistent cancer pain otherwise controlled with maintenance doses of opioid medications including at least 60 mg morphine/day, 50 mcg transdermal fentanyl/hour, or an equianalgesic dose of another opioid for a week or longer.

In two dose titration studies 95 of 127 patients (75%) who were on stable doses of either long-acting oral opioids or transdermal fentanyl for their persistent cancer pain titrated to a successful dose of oral transmucosal fentanyl citrate to treat their breakthrough cancer pain within the dose range offered (200, 400, 600, 800, 1200, and 1600 mcg). A “successful” dose was defined as a dose where one unit of oral transmucosal fentanyl citrate could be used consistently for at least two consecutive days to treat breakthrough cancer pain without unacceptable side effects. In these studies 11% of patients withdrew due to adverse reactions and 14% withdrew due to other reasons.

The successful dose of oral transmucosal fentanyl citrate for breakthrough cancer pain was not predicted from the daily maintenance dose of opioid used to manage the persistent cancer pain and is thus best determined by dose titration.

A double-blind placebo controlled crossover study was performed in cancer patients to evaluate the effectiveness of oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain. Of 130 patients who entered the study 92 patients (71%) achieved a successful dose during the titration phase. The distribution of successful doses is shown in Table 5.

On average, patients over 65 years of age titrated to a mean dose that was about 200 mcg less than the mean dose to which younger adult patients were titrated.

Oral transmucosal fentanyl citrate was administered beginning at Time 0 minutes and produced more pain relief compared with placebo at 15, 30, 45, and 60 minutes as measured after the start of administration (See Figure 2). The differences were statistically significant.

Figure 2.  
Pain Relief (PR) Scores (Mean±SD) During the Double-Blind Phase ─ All Patients with Evaluable Episodes on Both Oral Transmucosal Fentanyl Citrate and Placebo (N=86)
Essential tremor (ET) is the most common neurological movement disorder, affecting up to 1% of the population and up to 5% of individuals over the age of 65. ET is characterized by often disabling tremors that occur when an individual moves. The tremors most commonly affect the hands, head, voice, and legs in order of frequency, leading to impairment in activities of daily living and morbidity. No pharmacological agent has been developed for ET, though existing agents such as propranolol and primidone are used off-label to reduce tremor amplitude. Deep brain stimulation surgery is often reserved for only individuals with the most severe tremors. Patients with ET have long reported tremor benefits with the use of cannabis, though no controlled trials have been conducted. The investigators plan to conduct the first double-blind, placebo-control clinical trial of cannabis in an oral capsule. Various validated tremor rating methods will be used to quantify tremor severity, while looking at tolerability and safety.
The invention relates to a Chinese herbal medicine preparation for treating tuberculosis. Raw materials of the Chinese herbal medicine preparation comprise: panax ginseng, unibract fritillary bulb, Chinese caterpillar fungus, giant gecko, rose mallow root, common nandina fruit, turtle shell, coptis chinensis, dried human placenta, ilex asprella (Hook. et Arn.) champ. ex benth., zaocys dhumnades, szechwan lovage rhizome and angelica. The preparation method for the Chinese herbal medicine preparation comprises: crushing the Chinese herbal medicine into powders, preparing the powders into capsules or powder or pills, wherein the preferred formulation is the capsule with the specification of 0.5 g/granule. The Chinese herbal medicine preparation is provided for treating the tuberculosis, and has characteristics of rapid effect, no adverse reaction and good treatment effect.
PROBLEM TO BE SOLVED: To obtain a blood platelet factor producing agent useful for treating and preventing thromboxytepenia, having megakaryocyte apophysis forming activity, capable of producing blood platelet. SOLUTION: This blood platelet factor producing factor has the below- mentioned properties (a) to (d). (a) The blood platelet factor has megakaryocyte apophysis forming activity. (b) The activity is not neutralized by an interleukin-6 and erythropoietin neutralizing antiboty. (c) The blood platelet factor is adsorbed on a wheat embryo bud lectin under a condition of a buffer solution of 10mM N-(2-hyroxyethyl)piperazine-N'-2-ethanesulfonic acid (HEPES) having pH7.4, containing 150mM salt. (d) The blood platelet factor is not adsorbed on a blue coloring matter under a condition of a buffer solution of 10mM phosphoric acid (PBS), having pH7.4, containing 136mM salt and 2.7mM potassium chloride. A method for producing the blood platelet and its use as a medicine are also provided.